| ||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
Search results for: "M"
Results 81 - 90 of 604 shown below 
|
||||||||
|
||||||||
|
||||||||
|
||||||||
| mapping N Miura, N Onuki, A Rathi, A Virmani, S Nakamoto, Y Kishimoto, Y Murawaki, H Kawasaki, J Hasegawa, M Oshimura, W D Travis and A F Gazdar hTR repressor-related gene on human chromosome 10p15.1 doi:10.1054/bjoc.2001.2121 Abstract | Full article | PDF |
||||||||
| margins H K Tan, P Saulnier, A Auperin, L Lacroix, O Casiraghi, F Janot, P Fouret and S Temam Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas advance online publication, 2008-07-01 00:00:00.000; doi:10.1038/sj.bjc.6604478 Abstract | Full article | PDF |
||||||||
| marimastat S R Bramhall, M T Hallissey, J Whiting, J Scholefield, G Tierney, R C Stuart, R E Hawkins, P McCulloch, T Maughan, P D Brown, M Baillet and J W L Fielding Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial doi:10.1038/sj.bjc.6600310 Abstract | Full article | PDF S R Bramhall, J Schulz, J Nemunaitis, P D Brown, M Baillet and J A C Buckels A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer doi:10.1038/sj.bjc.6600446 Abstract | Full article | PDF J N Primrose, H Bleiberg, F Daniel, S Van Belle, M Seymour, M Baillet, K Barker, A Berrington and K P Lynch Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen doi:10.1038/sj.bjc.6690079 Abstract | Full article | PDF S A Watson, T M Morris, H M Collins, L J Bawden, K Hawkins and E A Bone Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA doi:10.1038/sj.bjc.6690645 Abstract | Full article | PDF J D Evans, A Stark, C D Johnson, F Daniel, J Carmichael, J Buckels, C W Imrie, P Brown and J P Neoptolemos A phase II trial of marimastat in advanced pancreatic cancer doi:10.1054/bjoc.2001.2168 Abstract | Full article | PDF |
||||||||
| marine natural compounds E Erba, M Serafini, G Gaipa, G Tognon, S Marchini, N Celli, D Rotilio, M Broggini, J Jimeno, G T Faircloth, A Biondi and M D'Incalci Effect of Aplidin in acute lymphoblastic leukaemia cells doi:10.1038/sj.bjc.6601130 Abstract | Full article | PDF |
||||||||
| marker P H Watson, S K Chia, C C Wykoff, C Han, R D Leek, W S Sly, K C Gatter, P Ratcliffe and A L Harris Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma doi:10.1038/sj.bjc.6600796 Abstract | Full article | PDF R D Riley, K R Abrams, A J Sutton, P C Lambert, D R Jones, D Heney and S A Burchill Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future doi:10.1038/sj.bjc.6600886 Abstract | Full article | PDF S Staibano, F Merolla, D Testa, R Iovine, M Mascolo, V Guarino, M D Castellone, M Di Benedetto, V Galli, S Motta, R M Melillo, G De Rosa, M Santoro and A Celetti OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome advance online publication, 2007-11-06 00:00:00.000; doi:10.1038/sj.bjc.6604070 Abstract | Full article | PDF H Uemura, Y Nakagawa, K Yoshida, S Saga, K Yoshikawa, Y Hirao and E Oosterwijk MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas doi:10.1038/sj.bjc.6690757 Abstract | Full article | PDF |
||||||||
| marker expression K A Landers, H Samaratunga, L Teng, M Buck, M J Burger, B Scells, M F Lavin and R A Gardiner Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer advance online publication, 2008-07-22 00:00:00.000; doi:10.1038/sj.bjc.6604486 Abstract | Full article | PDF E A Dublin, R R Millis, P Smith and L G Bobrow Minimal breast cancer: evaluation of histology and biological marker expression doi:10.1038/sj.bjc.6690570 Abstract | Full article | PDF |
||||||||
| marker genes B Weigelt, A J Bosma, A A M Hart, S Rodenhuis and L J van 't Veer Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients doi:10.1038/sj.bjc.6600868 Abstract | Full article | PDF |
||||||||
| markers M McCallum, C Baker, K Gillespie, B Cohen, H Stewart, R Leonard, D Cameron, R Leake, J Paxton, A Robertson, C Purdie, A Gould and M Steel A prognostic index for operable, node-negative breast cancer advance online publication, 2004-04-27 00:00:00.000; doi:10.1038/sj.bjc.6601826 Abstract | Full article | PDF M Wager, P Menei, J Guilhot, P Levillain, S Michalak, B Bataille, J-L Blanc, F Lapierre, P Rigoard, S Milin, F Duthe, D Bonneau, C-J Larsen and L Karayan-Tapon Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study advance online publication, 2008-05-27 00:00:00.000; doi:10.1038/sj.bjc.6604378 Abstract | Full article | PDF Z Popov, S Gil-Diez de Medina, M-A Lefrere-Belda, A Hoznek, S Bastuji-Garin, C C Abbou, J P Thiery, F Radvanyi and D K Chopin Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information doi:10.1054/bjoc.2000.1233 Abstract | Full article | PDF |
||||||||
| marketing approval G Apolone, R Joppi, V Bertele' and S Garattini Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures advance online publication, 2005-08-23 00:00:00.000; doi:10.1038/sj.bjc.6602750 Abstract | Full article | PDF |
||||||||
| Markov model C-D Chen, M-F Yen, W-M Wang, J-M Wong and TH-H Chen A case–cohort study for the disease natural history of adenoma–carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy doi:10.1038/sj.bjc.6601007 Abstract | Full article | PDF C Chouaïd, L Molinier, C Combescure, J P Daurès, B Housset and A Vergnenègre Economics of the clinical management of lung cancer in France: an analysis using a Markov model doi:10.1038/sj.bjc.6601547 Abstract | Full article | PDF J-M Boher, J-L Pujol, J Grenier and J-P Daurès Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis doi:10.1038/sj.bjc.6690227 Abstract | Full article | PDF |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2008 Cancer Research UK | ||
| |||
| Privacy Policy | |||